Lysergic acid diethylamide

Generic Name: Lysergic acid diethylamide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅N_₃O

CAS Number: 50-37-3

Unique Ingredient Identifier: 8NA5SWF92O

Background: Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies accordi...

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality

Phase 1

Recruiting

Conditions: Prosocial Behavior

Interventions: Drug: LSD
Drug: Ethanol

First Posted Date: 2023-01-04

Last Posted Date: 2023-01-04

Lead Sponsor: Maastricht University

Target Recruit Count: 60

Registration Number: NCT05670184

Locations: 🇳🇱
Maastricht University, Maastricht, Netherlands

LSD Treatment for Persons With Alcohol Use Disorder

Phase 2

Not yet recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: Active placebo
Drug: LSD

First Posted Date: 2022-07-26

Last Posted Date: 2023-10-18

Lead Sponsor: Felix Mueller

Target Recruit Count: 126

Registration Number: NCT05474989

Locations: 🇨🇭
University Hospital of Psychiatry, University of Bern, Bern, Switzerland
🇨🇭
University Hospital of Psychiatry, University of Basel, Basel, Switzerland

Effects of LSD on Neuroplasticity in Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy

Interventions: Drug: Lysergic Acid Diethylamide

First Posted Date: 2022-01-04

Last Posted Date: 2023-11-29

Lead Sponsor: University of Fribourg

Target Recruit Count: 40

Registration Number: NCT05177419

Locations: 🇨🇭
University of Fribourg, Fribourg, FR, Switzerland

Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Paroxetine
Drug: Lysergic Acid Diethylamide
Drug: Placebo

First Posted Date: 2022-01-03

Last Posted Date: 2024-03-13

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT05175430

Locations: 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Effect of Ketanserin After LSD Administration

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lysergic Acid Diethylamide
Drug: Ketanserin Placebo
Drug: Ketanserin

First Posted Date: 2020-09-22

Last Posted Date: 2021-10-21

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT04558294

Locations: 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lysergic Acid Diethylamide
Drug: 3,4-methylenedioxymethamphetamine
Other: MDMA Placebo
Other: LSD Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2022-08-23

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT04516902

Locations: 🇨🇭
University Hospital Basel, Clinical Trial Unit, Basel, BS, Switzerland

Comparative Acute Effects of LSD, Psilocybin and Mescaline

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mescaline
Other: Placebo
Drug: LSD
Drug: Psilocybin

First Posted Date: 2020-01-14

Last Posted Date: 2024-01-24

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 32

Registration Number: NCT04227756

Locations: 🇨🇭
University Hospital Basel, Clinical Trial Unit, Basel, BS, Switzerland

LSD Therapy for Persons Suffering From Major Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LSD

First Posted Date: 2019-03-07

Last Posted Date: 2023-03-29

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 60

Registration Number: NCT03866252

Locations: 🇨🇭
Universitäre Psychiatrische Kliniken, Basel, Basel-Stadt, Switzerland

Mood Effects of Serotonin Agonists

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lysergic Acid Diethylamide

First Posted Date: 2018-12-31

Last Posted Date: 2024-01-24

Lead Sponsor: University of Chicago

Target Recruit Count: 80

Registration Number: NCT03790358

Locations: 🇺🇸
Matthew Bona, Chicago, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache

Phase 2

Recruiting

Conditions: Cluster Headache

Interventions: Drug: Lysergic Acid Diethylamide
Drug: Placebo

First Posted Date: 2018-12-19

Last Posted Date: 2024-02-14

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 30

Registration Number: NCT03781128

Locations: 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy